KR20160034404A - Ｆc-함유 폴리펩타이드의 안정화 - Google Patents

Ｆc-함유 폴리펩타이드의 안정화 Download PDF

Info

Publication number
KR20160034404A
KR20160034404A KR1020167004786A KR20167004786A KR20160034404A KR 20160034404 A KR20160034404 A KR 20160034404A KR 1020167004786 A KR1020167004786 A KR 1020167004786A KR 20167004786 A KR20167004786 A KR 20167004786A KR 20160034404 A KR20160034404 A KR 20160034404A
Authority
KR
South Korea
Prior art keywords
val
pro
ser
thr
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167004786A
Other languages
English (en)
Korean (ko)
Inventor
구나세카란 카난
제니퍼 라발리
프레더릭 더블유. 야콥센
Original Assignee
암젠 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 암젠 인크 filed Critical 암젠 인크
Priority to KR1020237032656A priority Critical patent/KR20230141929A/ko
Publication of KR20160034404A publication Critical patent/KR20160034404A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
KR1020167004786A 2013-07-31 2014-07-30 Ｆc-함유 폴리펩타이드의 안정화 Ceased KR20160034404A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237032656A KR20230141929A (ko) 2013-07-31 2014-07-30 Ｆc-함유 폴리펩타이드의 안정화

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361860800P 2013-07-31 2013-07-31
US61/860,800 2013-07-31
PCT/US2014/048908 WO2015017548A2 (en) 2013-07-31 2014-07-30 Stabilization of fc-containing polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237032656A Division KR20230141929A (ko) 2013-07-31 2014-07-30 Ｆc-함유 폴리펩타이드의 안정화

Publications (1)

Publication Number Publication Date
KR20160034404A true KR20160034404A (ko) 2016-03-29

Family

ID=52432568

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020167004786A Ceased KR20160034404A (ko) 2013-07-31 2014-07-30 Ｆc-함유 폴리펩타이드의 안정화
KR1020257032842A Pending KR20250152665A (ko) 2013-07-31 2014-07-30 Ｆc-함유 폴리펩타이드의 안정화
KR1020237032656A Ceased KR20230141929A (ko) 2013-07-31 2014-07-30 Ｆc-함유 폴리펩타이드의 안정화

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020257032842A Pending KR20250152665A (ko) 2013-07-31 2014-07-30 Ｆc-함유 폴리펩타이드의 안정화
KR1020237032656A Ceased KR20230141929A (ko) 2013-07-31 2014-07-30 Ｆc-함유 폴리펩타이드의 안정화

Country Status (15)

Country Link
US (3) US20160193295A1 (enExample)
EP (1) EP3027647A4 (enExample)
JP (2) JP2016526909A (enExample)
KR (3) KR20160034404A (enExample)
CN (1) CN105658664A (enExample)
AU (3) AU2014296215A1 (enExample)
BR (1) BR112016002219A2 (enExample)
CA (1) CA2919076C (enExample)
CL (1) CL2016000232A1 (enExample)
EA (1) EA035319B1 (enExample)
HK (1) HK1224203A1 (enExample)
IL (1) IL243690B (enExample)
MX (2) MX2016001165A (enExample)
SG (1) SG11201600734YA (enExample)
WO (1) WO2015017548A2 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
WO2014120619A2 (en) 2013-01-30 2014-08-07 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
FR3012453B1 (fr) 2013-10-31 2015-11-13 Lab Francais Du Fractionnement Proteine chimerique dans le traitement de l’amylose
UA123432C2 (uk) 2014-07-30 2021-04-07 Нджм Біофармасьютікалз, Інк. Димер та спосіб його застосування для лікування метаболічних розладів
ES2799503T3 (es) * 2014-10-31 2020-12-18 Ngm Biopharmaceuticals Inc Composiciones y procedimientos de uso para el tratamiento de trastornos metabólicos
WO2016100788A1 (en) 2014-12-19 2016-06-23 Alkermes, Inc. Single chain fc fusion proteins
IL256989B (en) 2015-08-07 2022-08-01 Alx Oncology Inc Constructs with a sirp-alpha site or a variant thereof
CA3025162A1 (en) 2016-05-26 2017-11-30 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
CA3026393C (en) 2016-06-22 2023-03-14 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
MX2019007611A (es) * 2016-12-22 2020-07-29 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso.
EP3576789B1 (en) * 2017-02-01 2024-12-11 Zhejiang Shimai Pharmaceutical Co., Ltd. MONOMERIC HUMAN IgG1 Fc AND BISPECIFIC ANTIBODIES
IL271837B2 (en) * 2017-07-07 2024-01-01 Hanmi Pharm Ind Co Ltd Novel therapeutic enzyme fusion protein and use thereof
CA3071337A1 (en) * 2017-08-15 2019-02-21 Kindred Biosciences, Inc. Igg fc variants for veterinary use
CN107540748B (zh) * 2017-09-15 2020-07-14 北京伟杰信生物科技有限公司 长效重组猪fsh融合蛋白及其制备方法与应用
US12435328B2 (en) * 2017-12-22 2025-10-07 Hanmi Pharm. Co., Ltd. Therapeutic enzyme fusion protein having a novel structure and use thereof
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
CN109021109A (zh) * 2018-07-20 2018-12-18 上海交通大学 一种牛源性抗金黄色葡萄球菌融合抗体scFv-Fc及其制备方法
KR20210042117A (ko) 2018-08-03 2021-04-16 암젠 리서치 (뮌헨) 게엠베하 Cldn18.2 및 cd3에 대한 항체 작제물
KR102148405B1 (ko) * 2018-09-19 2020-08-27 주식회사 바이오앱 돼지의 Fc 단편을 포함하는 재조합 벡터 및 상기 벡터를 이용한 재조합 단백질의 제조 방법
KR102200773B1 (ko) * 2018-09-19 2021-01-12 주식회사 바이오앱 돼지의 Fc 단편과 융합된 항원 및 이를 포함하는 백신 조성물
US10947278B2 (en) * 2018-09-19 2021-03-16 Bioapplications Inc. Recombinant vector comprising porcine FC fragment and preparation method of recombinant protein using thereof
WO2020167957A1 (en) * 2019-02-12 2020-08-20 Board Of Regents, The University Of Texas System High affinity engineered t-cell receptors targeting cmv infected cells
KR20220044904A (ko) 2019-05-31 2022-04-12 알렉소 온콜로지 인크. 면역 관문 억제제와 병용하는 sirp 알파 fc 융합으로 암을 치료하는 방법
JP7661245B2 (ja) 2019-06-07 2025-04-14 アムジエン・インコーポレーテツド 二重特異性結合構築物
WO2021053556A1 (en) * 2019-09-18 2021-03-25 Novartis Ag Nkg2d fusion proteins and uses thereof
US11542276B2 (en) 2019-11-25 2023-01-03 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
AU2020400805B2 (en) * 2019-12-11 2024-03-28 Lg Chem, Ltd. Fusion polypeptide comprising GDF15 and polypeptide region capable of O-glycosylation
US20230093169A1 (en) 2020-01-22 2023-03-23 Amgen Research (Munch) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
JP7481856B2 (ja) * 2020-02-25 2024-05-13 シスメックス株式会社 改変抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法
CN111285936A (zh) * 2020-03-11 2020-06-16 北京双赢科创生物科技有限公司 靶向肿瘤的酸性敏感纳米肽段及其应用
TW202200615A (zh) 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
JP2023527293A (ja) 2020-05-19 2023-06-28 アムジエン・インコーポレーテツド Ｍａｇｅｂ２結合構築物
CN116096736A (zh) * 2020-08-14 2023-05-09 武汉友微生物技术有限公司 新型冠状病毒rbd融合蛋白
US20230322860A1 (en) * 2020-08-21 2023-10-12 Ajou University Industry-Academic Cooperation Foundation ANTIBODY FRAGMENT CONSISTING OF HEAVY CHAIN AND LIGHT CHAIN CONSTANT REGIONS IN WHICH GAMMA CONSTANT REGION (Cgamma1) AND EPSILON CONSTANT REGION (CE2-4) ARE FUSED, AND USE THEREOF
CN114426974B (zh) * 2020-10-29 2023-11-21 洛阳普泰生物技术有限公司 特异性结合非洲猪瘟病毒CD2v蛋白的抗体或抗体片段
KR20230097061A (ko) * 2020-11-02 2023-06-30 아트라러스, 인크. Sap fc 융합 단백질 및 사용 방법
TW202233679A (zh) 2020-11-06 2022-09-01 德商安美基研究（慕尼黑）公司 選擇性地與cldn6和cd3結合的多肽構建體
JP2023552375A (ja) * 2020-12-06 2023-12-15 エーエルエックス オンコロジー インコーポレイテッド 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための多量体
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
CA3216908A1 (en) 2021-05-13 2022-11-17 ALX Oncology Inc. Combination therapies for treating cancer
EP4392461A4 (en) * 2021-08-24 2025-10-15 Sunshine Lake Pharma Co Ltd GDF15 FUSION PROTEINS AND THEIR USES
CN116064562A (zh) * 2022-10-28 2023-05-05 江南大学 玉米赤霉烯酮的真核表达单链抗体以及全长抗体的制备方法以及用途
CN116284455B (zh) * 2023-04-17 2024-10-11 北京康乐卫士生物技术股份有限公司 一种带状疱疹病毒疫苗的嵌合抗原及其应用
WO2025036564A1 (de) * 2023-08-17 2025-02-20 Gottfried Wilhelm Leibniz Universität Hannover (Luh) Nukleinsäuresequenz, vektor, screening-verfahren und verfahren zur herstellung von rekombinanten antikörpern
WO2025162458A1 (zh) * 2024-02-04 2025-08-07 南通壹宸生物医药科技有限公司 融合抗体及其制备和应用
CN118344462B (zh) * 2024-06-18 2024-11-08 苏州易合医药有限公司 一种用于肺部给药的索马鲁肽突变体、融合蛋白及相关产品
CN119613573B (zh) * 2025-02-14 2025-05-30 浙江大学 一种CD40L-Fc融合蛋白、基因片段、重组质粒、重组细胞以及制备方法和用途
CN119735654B (zh) * 2025-02-27 2025-07-01 浙江海隆生物科技股份有限公司 一种牛副流感病毒的亚单位hn蛋白制备方法和应用
CN120623322B (zh) * 2025-08-14 2025-12-05 成都蓉生药业有限责任公司 一种人IgG Fc变体、基因片段、表达载体、宿主细胞、IgG抗体及人IgG Fc变体制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
ES2246069T3 (es) * 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
US20030207346A1 (en) * 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754209B2 (en) * 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
AU2005282700A1 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
EA016609B1 (ru) * 2005-11-28 2012-06-29 Генмаб А/С Рекомбинантные моновалентные антитела и способы их получения
JP2013511281A (ja) * 2009-11-23 2013-04-04 アムジェン インコーポレイテッド 単量体抗体Ｆｃ
MX379481B (es) 2010-12-06 2025-03-11 Seagen Inc Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer

Also Published As

Publication number Publication date
US20190192628A1 (en) 2019-06-27
WO2015017548A2 (en) 2015-02-05
CN105658664A (zh) 2016-06-08
MX2022008013A (es) 2022-07-27
US20160193295A1 (en) 2016-07-07
JP7344858B2 (ja) 2023-09-14
AU2022201204B2 (en) 2025-01-02
KR20230141929A (ko) 2023-10-10
CL2016000232A1 (es) 2016-09-02
IL243690A0 (en) 2016-04-21
US20250325631A1 (en) 2025-10-23
SG11201600734YA (en) 2016-02-26
EA035319B1 (ru) 2020-05-27
MX2016001165A (es) 2016-06-29
AU2014296215A1 (en) 2016-02-11
EP3027647A2 (en) 2016-06-08
CA2919076A1 (en) 2015-02-05
CA2919076C (en) 2024-01-30
JP2016526909A (ja) 2016-09-08
EA201690299A1 (ru) 2016-11-30
JP2021019598A (ja) 2021-02-18
WO2015017548A3 (en) 2015-11-05
BR112016002219A2 (pt) 2017-09-12
AU2020200329A1 (en) 2020-02-06
EP3027647A4 (en) 2017-01-04
KR20250152665A (ko) 2025-10-23
IL243690B (en) 2022-09-01
HK1224203A1 (zh) 2017-08-18
AU2022201204A1 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
AU2022201204B2 (en) Stabilization of Fc-containing polypeptides
JP6329585B2 (ja) 単量体抗体Ｆｃ
CN110234355B (zh) 单体人IgG1 Fc和双特异性抗体
EP2451840B1 (en) Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering
KR102590061B1 (ko) 유전자 조작 Fc 작제물에 관한 조성물 및 방법
JP2025513230A (ja) 変異体軽鎖フレームワーク領域を備える単鎖可変領域フラグメント
US12054552B2 (en) Humanized anti-IL-1R3 antibody and methods of use

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160224

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190726

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201112

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210923

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220727

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210923

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20201112

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220727

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210512

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190726

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221118

Patent event code: PE09021S01D

AMND Amendment
PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20230621

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20230203

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20221118

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20221020

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20220727

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20210923

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210512

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20201112

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190726

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20230922

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20230621

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20220727

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2023101002028

Request date: 20230922

J301 Trial decision

Free format text: TRIAL NUMBER: 2023101002028; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20230922

Effective date: 20240530

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20240530

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20230922

Decision date: 20240530

Appeal identifier: 2023101002028